Logo

Regeneron Reports the US FDA's Acceptance of Priority Review for REGN-EB3's BLA to Treat Ebola

Share this

Regeneron Reports the US FDA's Acceptance of Priority Review for REGN-EB3's BLA to Treat Ebola

Shots:

  • The BLA is supported by PALM clinical study conducted in the Democratic Republic of Congo. In Aug’2019- the trial was stopped early when preliminary results demonstrated that REGN-EB showed superiority over ZMapp
  • REGN-EB3 demonstrated superior efficacy as compared to ZMapp across multiple measures- including reduced mortality and fewer days until the Ebola virus was no longer detected in the bloodstream
  • REGN-EB3 is being developed under an ongoing collaboration with BARDA by utilizing VelociSuite technology and has received the US FDA’s ODD & BT designation with its anticipated PDUFA date as Oct 25- 2020. Regeneron is now utilizing VelociSuite technology to treat COVID-19 with the expected initiation of the clinical trial in June

Click here ­to­ read full press release/ article | Ref: Regeneron | Image: Regeneron


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions